Table 1.

Demographic and Clinical Data of PD Patients in APF Group and NPF Group

	Patients with PD
Clinical demographics	APF group, n = 25	NPF group, n = 25	P-value
Age (years)	63 ± 11	62 ± 7	0.828
Sex (male/female)	13/12	14/11	0.777
GMV	546.0 ± 75.0	578.6 ± 57.8	0.098
WMV	432.1 ± 57.3	432.6 ± 45.4	0.871
TIV	1337.6 ± 134.4	1364.6 ± 133.7	0.441
Pulmonary function parameters
FVC (% pred)	85.4 ± 20.4	99.8 ± 13.6	0.030*
FEV1 (% pred)	84.1 ± 19.1	105.9 ± 14.0	< 0.001*
FEV1/FVC	79.7 ± 9.0	86.7 ± 4.9	< 0.001*
MEF 50 (%)	63.2 ± 22.9	98.7 ± 14.2	< 0.001*
SpO2 (%)	94.5 ± 3.4	94.3 ± 2.7	0.756
Disease severity scale
UPDRS I	4.1 ± 3.6	3.3 ± 2.5	0.435
UPDRS II	12.5 ± 9.7	9.7 ± 5.6	0.311
UPDRS III	28.8 ± 23.0	23.5 ± 11.8	0.396
UPDRS total	45.4 ± 35.1	36.5 ± 18.8	0.357
Modified H & Y	2.2 ± 1.3	1.8 ± 0.9	0.276
S & E	78.3 ± 20.8	86.7 ± 11.1	0.128
Inflammatory markers
TBARS (µM/L)	13.9 ± 5.1	13.1 ± 5.1	0.520
Thiol (µM/L)	1.3 ± 0.5	1.5 ± 0.4	0.360
ICAM-1	215.1 ± 65.6	195.3 ± 75.8	0.514
P-selectin	100.5 ± 18.1	97.0 ± 13.0	0.314
E-selectin	42.6 ± 18.3	34.0 ± 18.0	0.243
CD133+CD34+ (%)	18.4 ± 16.1	27.7 ± 27.9	0.195
KDR+CD34+ (%)	3.5 ± 4.5	3.2 ± 4.7	0.943

APF abnormal pulmonary function, EPC epithelial progenitor cell, F female, FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, GMV gray matter volume, ICAM-1 intercellular adhesion molecule 1, KDR kinase insert domain-conjugating receptor, M male, MEF50 maximal expiratory flow after expiration of 50% of FVC, modified H & Y modified Hoehn and Yahr staging scale, NPF normal pulmonary function, PD Parkinson’s disease, SpO2 oxygen saturation, S & E Schwab and England Activities of Daily Living Scale, TIV total intracranial volume, TBARS thiobarbituric acid reactive substances, UPDRS Unified Parkinson Disease Rating Scale, WMV white matter volume

All data are presented as mean ± standard deviation. ^*P < 0.05